Summaries by Inventor Liu, Yongjian
Heo, Gyu Seong ; Liu, Yongjian ; Zhang, Xiuli
T-020196
— T-020196 CD163 Targeting Agent for Imaging and Therapy Technology Description Researchers in Yongjian Liu’s laboratory at Washington University have synthesized a new peptide-based CD163 radiotracer. CD163 is a well-known biomarker specific to macrophages implicated in multiple diseases, but…
CCR2-targeted cancer nanoimmunotherapyLim, Kian-Huat ; Liu, Yongjian ; Zhang, Xiaohui
T-019463
— Disease indication – Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide Drug class – First-in-class Target – CCR2, the receptor for CCL2 Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…
Broad spectrum chemokine receptor imaging agentLiu, Yongjian
T-019607
— 64Cu-DOTA-vMIP-II is a broad spectrum PET imaging agent that provides a non-invasive measurement of up to 10 chemokine receptors involved in the inflammatory processes of various diseases. This agent is based on the peptide vMIP-II (viral macrophage inflammatory protein-II), a viral CC chemokine enc…
Nanomaterials for Imaging and Treatment of AmyloidosisBieschke, Jan ; Guruswami, Sundaram ; Liu, Yongjian ; Sharma, Vijay
T-017876
— Background 8 million people per year are diagnosed with light-chain (AL) amyloidosis, a progressive disease than can quickly affect the kidney, heart, and nervous system if left untreated. The current method of diagnosis involves histological confirmation via biopsies of bone marrow, fat, and organ…
Nanomaterials for Imaging and Treatment of AmyloidosisBieschke, Jan ; Guruswami, Sundaram ; Liu, Yongjian ; Sharma, Vijay
T-017876
— Background 8 million people per year are diagnosed with light-chain (AL) amyloidosis, a progressive disease than can quickly affect the kidney, heart, and nervous system if left untreated. The current method of diagnosis involves histological confirmation via biopsies of bone marrow, fat, and organ…
